Please provide your email address to receive an email when new articles are posted on . Women with advanced ovarian cancer derived significant quality-adjusted PFS benefit from niraparib compared with ...
Management expects the interim PFS analysis for the HARMONi-3 squamous cohort in Q2 2026, with final PFS and interim OS data anticipated in the second half of the year. For the non-squamous cohort, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results